Areez Shafqat1*†
Mohamed H. Omer2†
Eman Nayaz Ahmed1
Ali Mushtaq3
Eman Ijaz1
Zara Ahmed1
Khaled Alkattan1
Ahmed Yaqinuddin1- 1College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
- 2School of Medicine, Cardiff University, Cardiff, United Kingdom
- 3Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, United States
A corrigendum on
Reprogramming the immunosuppressive tumor microenvironment: exploiting angiogenesis and thrombosis to enhance immunotherapy
by Shafqat A, Omer MH, Ahmed EN, Mushtaq A, Ijaz E, Ahmed Z, Alkattan K and Yaqinuddin A (2023). Front. Immunol. 14:1200941. doi: 10.3389/fimmu.2023.1200941
In the published article, there was an error in Figures 1 and 2 as published. Figures 1 and 2 were incorrectly switched, but the captions are correct.
The corrected Figures 1 and 2 and their captions appear below:
Figure 1 Pro-angiogenic signaling within the TME fosters tumor hypoxia. Tumor hypoxia generates an immunosuppressive tumor microenvironment—promoting the infiltration of MDSCs, M2 TAMs, Tregs, and exhausted CD8+ T-cells—that negatively impacts the efficacy of cancer immunotherapies. TME, tumor microenvironment; MDSCs, myeloid-derived suppressor cells; TAMs, tumor-associated macrophages.
Figure 2 The coagulome describes various components of the tumor microenvironment that modulate coagulation. CAT involves the activation of multiple pathways, including platelet activation, the coagulation cascade, and NETs production. These pathways also interact with various cells of the tumor immune microenvironment to facilitate tumor immune evasion and immunotherapy resistance. CAT, cancer-associated thrombosis; NETs, neutrophil extracellular traps.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: immunotherapy, tumor microenvironment, angiogenesis, thrombosis, vascular normalization, hypoxia, treatment resistance
Citation: Shafqat A, Omer MH, Ahmed EN, Mushtaq A, Ijaz E, Ahmed Z, Alkattan K and Yaqinuddin A (2023) Corrigendum: Reprogramming the immunosuppressive tumor microenvironment: exploiting angiogenesis and thrombosis to enhance immunotherapy. Front. Immunol. 14:1252998. doi: 10.3389/fimmu.2023.1252998
Received: 04 July 2023; Accepted: 05 July 2023;
Published: 13 July 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Shafqat, Omer, Ahmed, Mushtaq, Ijaz, Ahmed, Alkattan and Yaqinuddin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Areez Shafqat, ashafqat@alfaisal.edu
†These authors have contributed equally to this work and share first authorship